CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 7,769 enrolled
Drug / intervention
Pitavastatin +1 moredrug
Likely dose
Pitavastatin 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02344290
NCT02344290Phase 3Completed
CompareCT.gov

Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 22, 2015·Updated Sep 4, 2025

In Brief

A Phase 3 clinical trial evaluating Pitavastatin and Placebo for HIV and Cardiovascular Diseases. Completed, enrolled 7,769 participants across 137 sites in 13 countries.

Detailed Summary

People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART). The REPRIEVE trial consisted of two parallel identical protocols: * REPRIEVE (A5332) was funded by the NHLBI, with additional infrastructure support provided by the NIAID, and was conducted in U.S and select international sites (approximately 120 sites in 11 countries). * REPRIEVE (EU5332) was co-sponsored by NEAT ID and MGH, and was conducted at 13 sites in Spain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, Cardiovascular Diseases
CountriesBotswana, Brazil, Canada, Haiti, India, Peru, Puerto Rico, South Africa, Spain, Thailand, Uganda, United States, Zimbabwe
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Kowa Pharmaceuticals America, Inc., Gilead Sciences, Massachusetts General Hospital, NEAT ID Foundation

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 22, 2015
Enrollment StartMar 26, 2015
Primary CompletionAug 21, 2023
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 11.4 years ago

Interventions

Pitavastatindrug

One tablet (4 mg) taken once daily, orally with or without food

Placebodrug

One tablet taken once daily, orally with or without food